Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6935-6941

  Robinson, Blaine W ^a   Im, Michael M ^a   Ljungman, Mats ^a   Praz, Françoise ^b   Shewach, Donna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORO 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; COBALT 60; COMPLEMENTARY DNA; GEMCITABINE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IONIZING RADIATION; MISMATCH REPAIR; PRIORITY JOURNAL; RADIOSENSITIZATION; SOLID TUMOR; WESTERN BLOTTING;

BASE PAIR MISMATCH; CELL CYCLE; DEOXYADENINE NUCLEOTIDES; DEOXYCYTIDINE; DNA REPAIR; DNA, NEOPLASM; HCT116 CELLS; HUMANS; NUCLEOTIDES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 0142219871     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kaye, S. B. Gemcitabine: current status of Phase I and II trials. J. Clin. Oncol., 12: 1527-1531, 1994.
2. Rothenberg, M. L., Moore, M. J., Cripps, M. C., Anderson, J. S., Portenoy, R. K., Burris, H. A., Green, M. R., Tarassoff, P. G., Brown, T. D., Casper, E. S., Storniolo, A. M., and Von Hoff, D. D. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol., 7: 347-353, 1996.
3. Gatzemeier, U., Shepherd, F. A., Le Chevalier, T., Weynants, P., Cottier, B., Groen, H. J., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., Burkes, R. L., Gottfried, M., and Voi, M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter extended Phase II study. Eur. J. Cancer, 32A: 243-248, 1996.
4. Crino, L., Mosconi, A. M., Seagliotti, G., Selvaggi, G., Novello, S., Rinaldi, M., Della Giulia, M., Gridelli, C., Rossi, A., Calandri, C., De Marinis, F., Noseda, M., and Tonato, M. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a Phase II trial. J. Clin. Oncol., 17: 2081-2085, 1999.
5. Rockwell, S., and Grindey, G. B. Effect of 2′,2′ -difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol. Res., 4: 151-155, 1992.
6. Shewach, D. S., Hahn, T. M., Chang, E., Hertel, L. W., and Lawrence, T. S. Metabolism of 2′,2′-difluorodeoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res., 54: 3218-3223, 1994.
7. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst. (Bethesda), 88: 1193-1203, 1996.
8. Lawrence, T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W., and Shewach, D. S. Radiosensitization of pancreatic cancer cells by 2′,2′ -difluoro-2′-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys., 34: 867-872, 1996.
9. Joschko, M. A., Webster, L. K., Groves, J., Yuen, K., Palatsides, M., Ball, D. L., and Millward, M. J. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat. Oncol. Investig., 5: 62-71, 1997.
10. Milas, L., Fujii, T., Hunter, N., Elshaikh, M., Mason, K. A., Plunkett, W., Ang, K. K., and Hittelman, W. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res., 59: 107-114, 1999.
11. Gregoire, V., Cvilic, S., Beauduin, M., de Coster, B., Gueulette, J., Octave-Prignot, M., and Scalliet, P. Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice. Radiat. Res., 151: 747-749, 1999.
12. Fields, M. T., Eisbruch, A., Normolle, D., Orfali, A., Davis, M. A., Pu, A. T., and Lawrence, T. S. Radiosensitization produced in vivo by once- vs. twice-weekly 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Int. J. Radiat. Oncol. Biol. Phys., 47: 785-791, 2000.
13. Blackstock, A. W., Bernard, S. A., Richards, F., Eagle, K. S., Case, L. D., Poole, M. E., Savage, P. D., and Tepper, J. E. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J. Clin. Oncol., 17: 2208-2212, 1999.
14. Blackstock, A. W., Lesser, G. J., Fletcher-Steede, J., Case, L. D., Tustin, J. M., Russo, S. M., White, D. R., and Miller, A. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 51: 1281-1289, 2001.
15. Eisbruch, A., Shewach, D. S., Bradford, C. R., Littles, J. F., Teknos, T. N., Chepeha, D. B., Marentette, L. J., Terrell, J. E., Hogikyan, N. D., Dawson, L. A., Urba, S., Wolf, G. T., and Lawrence, T. S. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a Phase I trial and intracellular drug incorporation study. J. Clin. Oncol., 19: 792-799, 2001.
16. McGinn, C. J., Zalupski, M., Shurreiqi, I., Robertson, J. M., Eckhauser, F. E., Smith, D. C., Brown, D., Hejna, G., Strawderman, M., Normolle, D., and Lawrence, T. S. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced prancreatic cancer. J. Clin. Oncol., 19: 4202-4208, 2001.
17. Pipas, J. M., Mitchell, S. E., Barth, R. J., Vera-Gimon, R., Rathman, J., Meyer, L. P., Wagman, R. S., Lewis, L. D., McDonnell, C., Colacchio, T. A., and Perez, R. P. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys., 50: 1317-1322, 2001.
18. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. P. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′ -difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
19. Baker, C. H., Banzon, J., Bollinger, J. M., Stubbe, J., Samano, V., Robins, M. J., Lippert, B., Jarvi, E., and Resvick, R. 2′-Deoxy-2′ -methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem., 34: 1879-1884, 1991.
20. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-diflourodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
21. Ruiz van Haperen, V. W., Veerman, G., Vermorken, J. B., and Peters, G. J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol., 46: 762-766, 1993.
22. Ross, D. D., and Cuddy, D. P. Molecular effects of 2′,2′ -difluoro-deoxycytidine (gemcitabine) on DNA replication in intact HL-60 cells. Biochem. Pharmacol., 48: 1619-1630, 1994.
23. Huang, P., and Plunkett, W. Fludarabinc- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol., 36: 181-188, 1995.
24. Ostruszka, L. J., and Shewach, D. S. The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′ -deoxycytidine. Cancer Chemother. Pharmacol., in press, 2003.
25. Ling, L. L., and Ward, J. F. Radiosensitization of Chinese hamster V79 cells by bromodeoxyuridine substitution of thymidine: enhancement of radiation-induced toxicity and DNA strand break production by monofilar and bifilar substitution. Radiat. Res., 121: 76-83, 1990.
26. Miller, E. M., Fowler, J. F., and Kinsella, T. J. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine. Radiat. Res., 131: 90-97, 1992.
27. Iliakis, G., Kurtzman, S., Pantelias, G., and Okayasu, R. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat. Res., 119: 286-304, 1989.
28. Iliakis, G., and Kurtzman, S. Mechanism of radiosensitization by halogenated pyrimidines: bromodeoxyuridine and α-arabinofuranosyladenine affect similar subsets of radiation-induced potentially lethal lesions in plateau-phase Chinese hamster ovary cells. Radiat. Res., 127: 45-51, 1991.
29. Lawrence, T. S., Chang, E. Y., Hahn, T. M., and Shewach, D. S. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Clin. Cancer Res., 3: 777-782, 1997.
30. Shewach, D. S., and Lawrence, T. S. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin. Oncol., 22: 68-71, 1995.
31. Latz, D. L., Fleckenstein, K., Eble, M., Blatter, J., Wannenmacher, M., and Weber, K. J. Radiosensitizing potential of gemcitabine (2′,2′ -difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int. J. Radiat. Oncol. Biol. Phys., 41: 875-882, 1998.
32. Ostruszka, L., and Shewach, D. S. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res., 60: 6080-6088, 2000.
33. Schy, W. E., Hertel, L. W., Kroin, J. S., Bloom, L. B., Goodman, M. F., and Richardson, F. C. Effect of template-located 2′,2′ -difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klcnow (3′->5′ exonuclease-) fragment. Cancer Res., 53: 4582-4587, 1993.
34. Kunz, B. A. Genetic effects of deoxyribonucleotide pool imbalances. Environ. Mutagen., 4: 695-725, 1982.
35. Bebenek, K., Roberts, J. D., and Kunkel, T. A. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem., 267: 3589-3596, 1992.
36. Martomo, S. A., and Mathews, C. K. Effects of biological DNA precursor pool asymmetry upon accuracy of DNA replication in vitro. Mutat. Res., 499: 197-211, 2002.
37. Toft, N. J., and Arends, M. J. DNA mismatch repair and colorectal cancer. J. Pathol., 185: 123-129, 1998.
38. Wheeler, J. M., Bodmer, W. F., and Mortensen, N. J. DNA mismatch repair genes and colorectal cancer. Gut, 47: 148-153, 2000.
39. Peltomaki, P. DNA mismatch repair and cancer. Mutat. Res., 488: 77-85, 2001.
40. Jacob, S., and Praz, F. DNA mismatch repair defects: role in colorectal carcinogenesis. Biochimie (Paris), 84: 27-47, 2002.
41. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
42. Fink, D., Aebi, S., and Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 4: 1-6, 1998.
43. Jacob, S., Aguado, M., Fallik, D., and Praz, F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res., 61: 6555-6562, 2001.
44. Wu, J., Gu, L., Wang, H., Geacintov, N. E., and Li, G. Mismatch repair processing of careinogen-DNA adducts triggers apoptosis. Mol. Cell. Biol., 19: 8292-8301, 1999.
45. Lipkin, S. M., Wang, V., Jacoby, R., Banerjee-Basu, S., Baxevanis, A. D., Lynch, H. T., Elliott, R. M., and Collins, F. S. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat. Genet., 24: 27-35, 2000.
46. Kennedy, A. S., Harrison, G. H., Mansfield, C. M., Zhou, X. J., Xu, J. F., and Balcer-Knbiczek, E. K. Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect of TP53 or hMLH1 deficiency. Int. J. Cancer, 90: 175-185, 2000.
47. 2-M cells cycle checkpoint arrest following ionizing radiation. Cancer Res., 58: 767-778, 1998.
48. Robinson, B. W., Ljungman, M., and Shewach, D. S. Gemcitabine cytotoxicity and radiation sensitivity in mismatch repair proficient and deficient HCT116 cells. Proc. Am. Assoc. Cancer Res., 42: 3587, 2001.
49. Robinson, B. W., Ljungman, M., and Shewach, D. S. The effect of p53 status on gemcitabine cytotoxicity and radiation sensitivity in mismatch repair proficient and deficient HCT116 cells. Proc. Am. Assoc. Cancer Res., 43: 3947, 2002.
50. Fertil, B., Dertinger, H., Courdi, A., and Malaise, E. P. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat. Res., 99: 73-84, 1984.
51. Shewach, D. S. Quantitation of deoxyribonucleoside 5′ -triphosphates by a sequential boronate and anion-exchange high-pressure liquid chromatographic procedure. Anal. Biochem., 206: 178-182, 1992.
52. Hoy, C. A., Seamer, L. C., and Schimke, R. T. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. Cytometry, 10: 718-725, 1989.
53. Robinson, B. W., and Shewach, D. S. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin. Cancer Res., 7: 2581-2589, 2001.
54. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′ -nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res., 54: 4308-4312, 1994.
55. Gregoire, V., Beauduin, M., Bruniaux, M., de Coster, B., Octave-Prignot, M., and Scalliet, P. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int. J. Radiat. Biol., 73: 511-520, 1998.
56. Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., and Howell, S. B. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res., 61: 1508-1516, 2001.
57. Brown, R., Hirst, G. L., Gallagher, G. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., and Anthoney, D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997.
58. Fang, W., and Modrich, P. Human strand-specific mismatch repair occurs by a bidirectional mechanism similar to that of the bacterial reaction. J. Biol. Chem., 268: 11838-11844, 1993.
59. Fritzell, J. A., Narayanan, L., Baker, S. M., Bronner, C. E., Andrew, S. E., Prolla, T. A., Bradley, A., Jirik, F. R., Liskay, R. M., and Glazer, P. M. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res., 57: 5143-5147, 1997.
60. Berry, S. E., Garces, C., Hwang, H., Kunugi, K., Meyers, M., Davis, T. W., Boothman, D. A., and Kinsella, T. J. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res., 59: 1840-1845, 1999.
61. Berry, S. E., Davis, T. W., Schupp, J. E., Hwang, H., Wind, N., and Kinsella, T. J. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: MSH2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res., 60: 5773-5780, 2000.
62. Goz, B. The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol. Rev., 29: 249-272, 1978.
63. Shewach, D. S., Ellero, J., Maneini, W. R., and Ensminger, W. D. Decrease in TTP pools mediated by 5-bromo-2′-deoxycytidine exposure in a human glioblastoma cell line. Biochem. Pharmacol., 43: 1579-1585, 1992.
64. Taverna, P., Liu, L., Hanson, A. J., Monks, A., and Gerson, S. L. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in the cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol., 46: 507-516, 2000.